文献速递病毒性肝炎

Xpert® HCV检测在CLIA豁免站点指尖血中的性能评估

Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States.
PubMed 文献 · Clin Infect Dis · 2026-01-01

这项前瞻性观察性临床研究在美国15个CLIA豁免站点评估Xpert® HCV检测指尖血样本的性能。共纳入1279名参与者,985名结果有效者纳入分析,HCV抗体和RNA流行率分别为34.6%和12.4%。Xpert® HCV检测相对患者感染状态的阳性符合率为93.4%(95%CI: 87.6-96.6),阴性符合率为99.8%(95%CI: 99.2-99.9),结论为敏感、特异且可接受。

要点

  • Xpert® HCV检测指尖血阳性和阴性符合率分别为93.4%和99.8%。
  • 研究在CLIA豁免站点由自训人员采集指尖血,操作可行。
  • 该检测有望用于HCV RNA的即时检测,助力消除丙肝。

核心结论

  • Xpert® HCV检测指尖血样本检测HCV RNA敏感、特异且可接受。

研究设计与样本

  • 前瞻性观察性临床研究,在美国15个CLIA豁免站点纳入1279名有风险或症状的参与者,985名有效结果者纳入性能分析。

主要发现

  • HCV抗体流行率为34.6%,HCV RNA流行率为12.4%。
  • Xpert® HCV检测相对患者感染状态的阳性符合率为93.4%(95%CI: 87.6-96.6),阴性符合率为99.8%(95%CI: 99.2-99.9)。

临床怎么用

  • 可在CLIA豁免站点由自训人员采集指尖血使用Xpert® HCV检测HCV RNA,辅助诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A major barrier to hepatitis C virus (HCV) elimination in the United States is the lack of a point-of-care test to confirm the presence of HCV RNA. The purpose of this clinical trial was to evaluate the performance of the Xpert® HCV test at CLIA-waived sites in the United States. METHODS: Participants at risk and/or with signs/symptoms of HCV infection provided fingerstick blood that was tested on the Xpert® HCV test and venous blood tested using the cobas® HCV and Elecsys® Anti-HCV II tests. Fingerstick blood was collected at CLIA-waived sites by individuals self-trained on collection procedures. RESULTS: Participants (N = 1279) were enrolled across 15 sites; 1015 (79.3%) were deemed eligible for further evaluation. Specimens from 985 (97.0%) participants with valid results for Xpert®, cobas and Elecsys were included in the performance analysis. The prevalence of HCV antibodies and HCV RNA was 34.6% and 12.4%, respectively. The Xpert® HCV test demonstrated a positive percent agreement of 93.4% (95% CI: 87.6-96.6) and a negative percent agreement of 99.8% (95% CI: 99.2-99.9) relative to the patient infected status. CONCLUSIONS: Data from this clinical trial showed that the Xpert® HCV test was sensitive, specific, and acceptable for use to detect HCV RNA in human EDTA fingerstick blood from individuals at risk and/or with signs/symptoms of HCV infection. Clinical Trials Registration. This study, Pro0075996, was approved by Advarra IRB (Columbia, Maryland, 21044) and registered on ClinicalTrials.gov (NCT06508996).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Havens JR, Fluker SA, Schimmel J, et al. Performance Evaluation of the Xpert® HCV Test on Fingerstick Blood in a Prospective Observational Clinical Study at CLIA-Waived Sites in the United States. Clin Infect Dis. 2026. PMID: 41823658. doi:10.1093/cid/ciag173

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。